Spectrum Pharmaceuticals, Inc
PharmaHenderson, Nevada, United States · Est. 1987
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing oncology and hematology drugs.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
63
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Recent Activity
Last 14 days
Oct 29, 2026
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Oct 29, 2026
Suspended
A Randomized, Phase 3 Study of Poziotinib in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring HER2 Exon 20 Mutations (PINNACLE)
Earlier
Jul 29, 2026TrialAn Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Apr 8, 2021TrialA Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
Jan 1, 2021TrialA Study of IGN002 for Refractory NHL
Jun 23, 2020TrialStudy of Poziotinib in Japanese Patients With NSCLC
May 29, 2020TrialStudy of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects
Mar 11, 2020TrialOpen-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
4 more events
Dec 23, 2019TrialA Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Jun 25, 2019TrialA Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Jul 13, 2018TrialA Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Oct 13, 2017TrialPhase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
CEOJoe Turgeon
Founded1987
HQHenderson, Nevada, United States
Websitespectrumpharm.com
LinkedInCompany Page
Therapeutic Focus
hematologyoncologyprimary care
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)